针调节阿尔茨海默病的肠道微生物群:当前的证据,挑战和未来的机会
Long Yan1,2, Hong Li1,2, Yulin Qian1
1The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Frontiers in neuroscience
|March 18, 2024
概括
这篇评论探讨了针如何通过调节肠道微生物群来治疗阿尔茨海默病,为这种神经退行性疾病提供了潜在的新治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 胃肠病学 胃肠病学
- 综合医学是一个整体的医学.
背景情况:
- 阿尔茨海默病 (AD) 是一种流行的神经退行性疾病,缺乏有效的治疗方法.
- 肠道微生物群-大脑轴通过神经免疫和内分泌途径影响AD的发病.
- 针是肠道微生物组成的潜在调节剂.
研究的目的:
- 在阿尔茨海默病的背景下,审查针在调节肠道微生物群中的作用.
- 讨论针作为AD治疗干预的当前挑战和未来机会.
主要方法:
- 关于针,肠道微生物群和阿尔茨海默病的最新研究的文献综述.
- 分析了针,肠道微生物群和神经炎症之间的联系机制.
- 临床和临床前证据的探索.
主要成果:
- 针影响肠道微生物群的组成,可能会影响AD的进展.
- 针对肠道微生物群-大脑轴的调节可能会产生神经保护作用.
- 有证据表明,针可以作为AD的补充疗法.
结论:
- 针作为阿尔茨海默氏病的治疗策略,通过向肠道微生物群,显示出有前途.
- 需要进一步研究以阐明AD治疗和预防的机制和优化针方案.
- 探索针在肠道微生物群-大脑轴上的作用为AD管理提供了新的途径.
更多相关视频
03:26Author Spotlight: Improving Anesthesia Protocols for Enhanced Mouse Acupuncture Research
Published on: December 8, 2023
1.1K
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
11.9K
相关概念视频
Alzheimer's Disease: Treatment
186
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
186
Alzheimer's Disease: Overview
475
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
475
